NCT01029652 · OUTCOME
Physician's Assessment of Range of Motion of the Most Affected Joint
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study · Source last updated 2014-01-30
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- Not reported
- Time frame
- 72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (24 weeks overall)
What was measured
The study physician assessed the range of motion of the most affected joint for range of motion on a 5-point Likert scale: Normal, mildly restricted, moderately restricted, severely restricted, immobilized. The percentage of patients in each category is reported.
Analysis population: Full Analysis Set (FAS): All patients that received study drug. 'N' in each category indicates participants with observations analyzed for this endpoint at specified time points.
Groups in this outcome
Canakinumab 150 mg
Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.
Triamcinolone Acetonide 40 mg
Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Canakinumab 150 mg | 113 |
|---|
| Triamcinolone Acetonide 40 mg | 115 |
|---|
Reported measurements
Normal (Core) [N=113, 111]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 25.7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 31.5 | Not reported | Not reported | Not reported | Not reported |
|---|
Mildly restricted (Core) [N=113, 111]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 50.4 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 29.7 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately restricted (Core) [N=113, 111]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 21.2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 27.0 | Not reported | Not reported | Not reported | Not reported |
|---|
Severely restricted (Core) [N=113, 111]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 2.7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 8.1 | Not reported | Not reported | Not reported | Not reported |
|---|
Immobilized (Core) [N=113, 111]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 0.0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 3.6 | Not reported | Not reported | Not reported | Not reported |
|---|
Normal (24 weeks) [N=87, 79]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 66.7 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 65.8 | Not reported | Not reported | Not reported | Not reported |
|---|
Mildly restricted (24 weeks) [N=87, 79]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 31.0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 29.1 | Not reported | Not reported | Not reported | Not reported |
|---|
Moderately Restricted (24 weeks) [N=87, 79]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 2.3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 3.8 | Not reported | Not reported | Not reported | Not reported |
|---|
Severely Restricted (24 weeks) [N=87, 79]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 0.0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 1.3 | Not reported | Not reported | Not reported | Not reported |
|---|
Immobilized (24 weeks) [N=87, 79]
Values in Percentage of participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Canakinumab 150 mg | 0.0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Triamcinolone Acetonide 40 mg | 0.0 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 25.7
- group Id
- OG001
- value
- 31.5
- title
- Normal (Core) [N=113, 111]
- categories
- measurements
- group Id
- OG000
- value
- 50.4
- group Id
- OG001
- value
- 29.7
- title
- Mildly restricted (Core) [N=113, 111]
- categories
- measurements
- group Id
- OG000
- value
- 21.2
- group Id
- OG001
- value
- 27.0
- title
- Moderately restricted (Core) [N=113, 111]
- categories
- measurements
- group Id
- OG000
- value
- 2.7
- group Id
- OG001
- value
- 8.1
- title
- Severely restricted (Core) [N=113, 111]
- categories
- measurements
- group Id
- OG000
- value
- 0.0
- group Id
- OG001
- value
- 3.6
- title
- Immobilized (Core) [N=113, 111]
- categories
- measurements
- group Id
- OG000
- value
- 66.7
- group Id
- OG001
- value
- 65.8
- title
- Normal (24 weeks) [N=87, 79]
- categories
- measurements
- group Id
- OG000
- value
- 31.0
- group Id
- OG001
- value
- 29.1
- title
- Mildly restricted (24 weeks) [N=87, 79]
- categories
- measurements
- group Id
- OG000
- value
- 2.3
- group Id
- OG001
- value
- 3.8
- title
- Moderately Restricted (24 weeks) [N=87, 79]
- categories
- measurements
- group Id
- OG000
- value
- 0.0
- group Id
- OG001
- value
- 1.3
- title
- Severely Restricted (24 weeks) [N=87, 79]
- categories
- measurements
- group Id
- OG000
- value
- 0.0
- group Id
- OG001
- value
- 0.0
- title
- Immobilized (24 weeks) [N=87, 79]
- denoms
- counts
- group Id
- OG000
- value
- 113
- group Id
- OG001
- value
- 115
- units
- Participants
- description
- The study physician assessed the range of motion of the most affected joint for range of motion on a 5-point Likert scale: Normal, mildly restricted, moderately restricted, severely restricted, immobilized. The percentage of patients in each category is reported.
- groups
- description
- Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.
- id
- OG000
- title
- Canakinumab 150 mg
- description
- Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.
- id
- OG001
- title
- Triamcinolone Acetonide 40 mg
- param Type
- NUMBER
- population Description
- Full Analysis Set (FAS): All patients that received study drug. 'N' in each category indicates participants with observations analyzed for this endpoint at specified time points.
- reporting Status
- POSTED
- time Frame
- 72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (24 weeks overall)
- title
- Physician's Assessment of Range of Motion of the Most Affected Joint
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle